EUVIMEDEUVIMED entdecken
Multizentrische StudieRandomisierte kontrollierte Studie

The evaluation of atorvastatin as an adjunct to fluconazole for the anti-fungal prophylaxis in acute myeloid leukemia: a multicenter, triple-blinded, randomized clinical trial

Niloufar Saber-Moghaddam, Mohammad Moeini Nodeh, Vahid Ghavami, Hossein Rahimi, Sajjad Ataei Azimi, Mohsen Seddigh-Shamsi, Mostafa Kamandi, Abolghasem Allahyari, Somayeh Sadat Shariatmaghani, Sepideh Elyasi, Omid Arasteh

Naunyn-Schmiedeberg's Archives of Pharmacology · 2024

DOI: 10.1007/s00210-023-02892-w ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2024. Verfasst von Niloufar Saber-Moghaddam und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, Faculty of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran. Hauptthemen laut MEDLINE: Atorvastatin, Leukemia, Myeloid, Acute, Antifungal Agents, Fluconazole. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 61 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The development of invasive fungal infections (IFIs) is a serious complication in acute myeloid leukemia (AML) patients who undergo an induction to remission chemotherapy. Given the increased mortality in AML patients with IFI despite prophylaxis, we need to address this problem. Statins have traditionally been employed in clinical settings as agents for reducing lipid levels. Nonetheless, recent investigations have brought to light their antifungal properties in animals, as well as in vitro studies. The objective of this study was to assess the effectiveness of atorvastatin when added to the routine IFI prophylaxis regimen in patients diagnosed with AML. A randomized, multicenter, triple-blind study was conducted on 76 AML patients aged 18-70, who received either placebo or atorvastatin in addition to fluconazole. Patients were followed for 30 days in case of developing IFIs, patient survival, and atorvastatin- related adverse drug reactions. Data were analyzed with SPSS version 26.0. A level of significance of 0.05 was utilized as the threshold for all statistical tests. The data were analyzed by adjusting for the effect of age, regarding that there was a significant difference between the two groups, and showed that atorvastatin reduced the development of both probable and proven IFI (based on EORTC/MSGERC criteria) compared to placebo. IFI-free survival was also significantly better in the atorvastatin group. The incidence of developing aspergillosis did not differ between the two groups. No serious adverse events related to atorvastatin were observed. The present investigation has substantiated the antecedent in vitro and animal research on the fungicidal impact of statins and has suggested the need for additional research involving larger sample sizes and an extended duration of follow-up. Trial registration: This study was registered on the Iranian registry of clinical trials as IRCT20210503051166N1 (Date of confirmation 2021.05.03).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AtorvastatinLeukemia, Myeloid, AcuteAntifungal AgentsFluconazoleHumansMiddle AgedMaleFemaleAdultAgedYoung AdultAdolescentInvasive Fungal InfectionsHydroxymethylglutaryl-CoA Reductase InhibitorsDrug Therapy, CombinationDouble-Blind Method

Stichwörter der Autor:innen

Antifungal resistanceHematologic malignancyInvasive aspergillosisMucormycosisStatins

Substanzen

AtorvastatinAntifungal AgentsFluconazoleHydroxymethylglutaryl-CoA Reductase Inhibitors

Autor:innen und Institutionen

  • Department of Clinical Pharmacy, Faculty of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Department of Hematology-Oncology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Department of Epidemiology & Biostatistics, School of Health, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Department of Clinical Pharmacy, Faculty of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran. Arasteho@mums.ac.ir.

Zitieren

APA

Saber-Moghaddam, N., Nodeh, M. M., Ghavami, V., Rahimi, H., Azimi, S. A., Seddigh-Shamsi, M., Kamandi, M., Allahyari, A., Shariatmaghani, S. S., Elyasi, S., & Arasteh, O. (2024). The evaluation of atorvastatin as an adjunct to fluconazole for the anti-fungal prophylaxis in acute myeloid leukemia: a multicenter, triple-blinded, randomized clinical trial. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-023-02892-w

Vancouver

Saber-Moghaddam N, Nodeh MM, Ghavami V, Rahimi H, Azimi SA, Seddigh-Shamsi M, et al. The evaluation of atorvastatin as an adjunct to fluconazole for the anti-fungal prophylaxis in acute myeloid leukemia: a multicenter, triple-blinded, randomized clinical trial. Naunyn-Schmiedeberg's Archives of Pharmacology. 2024. doi:10.1007/s00210-023-02892-w

BibTeX
@article{SaberMoghaddam2024,
  author = {Saber-Moghaddam, Niloufar and Nodeh, Mohammad Moeini and Ghavami, Vahid and Rahimi, Hossein and Azimi, Sajjad Ataei and Seddigh-Shamsi, Mohsen and Kamandi, Mostafa and Allahyari, Abolghasem and Shariatmaghani, Somayeh Sadat and Elyasi, Sepideh and Arasteh, Omid},
  title = {The evaluation of atorvastatin as an adjunct to fluconazole for the anti-fungal prophylaxis in acute myeloid leukemia: a multicenter, triple-blinded, randomized clinical trial},
  journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
  year = {2024},
  doi = {10.1007/s00210-023-02892-w}
}
Kostenlos starten →